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nhibition of vaccine responses
to  the  infectious  pathogens  encountered  shortly  after  birth.  Maternal  antibody  is  actively  transported
across  the  placenta  and  serves  to  provide  protection  to  the  newborn  during  the  ﬁrst  weeks  to  months
of  life.  However,  maternal  antibody  has  been  shown  repeatedly  to inhibit  the  immune  responses  of
young  children  to  vaccines.  The  mechanisms  for  this  inhibition  are  presented  and  the  impact  on  ultimate
immune  responses  is discussed.
©  2015  The  Author.  Published  by Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY  licenseInfants are born with immature immune systems, making it dif-
cult for them to effectively respond to the infectious pathogens
ncountered shortly after birth. However, maternal antibody is
ctively transported across the placenta beginning at the end of
he second trimester and serves to provide protection to the infant
uring the ﬁrst weeks to months of life [1]. Most maternal anti-
odies are of the IgG isotype and are metabolized over time.
owever, even low-titer, non-protective levels of maternal anti-
odies have still been shown to inhibit infant immune responses
o vaccination. Immune responses to all types of vaccines, includ-
ng live-attenuated, inactivated, and subunit vaccines, have been
eported to be inhibited by the presence of maternal antibody [2].
peciﬁc antibodies elicited by vaccination, including IgA, IgM and
gG isotypes, are secreted into human colostrum and milk, with
ecretory IgA the predominant antibody class. During breastfeeding
hese ingested antibodies provide mucosal protection by inhibi-
ing the adhesion and invasion of both commensal and pathogenic
rganisms and by promoting their exclusion and neutralization [3].
In this review, we will use measles vaccine as a model to high-
ight the effect of maternal antibody on the immune responses
n young children since it has been extensively studied, although
any of these studies were performed several decades earlier. In
ddition, we will also summarize data where maternal antibod-
es inhibit the generation of infant antibody after other routinely
dministered vaccines. Finally, we will present new insights into
he mechanisms of inhibition by maternal antibody and focus on
otential ways to circumvent this inhibition. These new insights
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were comprehensively reviewed in an excellent overview on this
topic [2].
Measles vaccine: Measles vaccine is the best studied exam-
ple of the effect of maternal antibody on infant responses to
immunization. The original measles vaccine virus, the Edmonston
strain, was  developed by attenuating wild-type measles through
successive laboratory passages. Vaccination with the attenuated
strain induces neutralizing antibodies against the two major gly-
coproteins, hemagglutinin and fusion protein [4]. During their ﬁrst
year of life, children are protected from measles by neutralizing
antibodies provided through transplacentally acquired antibody.
However, over time, these antibody titers wane and no longer
provide protection against wild-type infection [5]. In clinical stud-
ies, immunization in the presence of maternal antibodies leads to
reduction in mortality [6] and morbidity [7]. However, solid lasting
immunity, including protective B cell responses, and the absence
of clinical symptoms after infection is not established after immu-
nization in the presence of maternal antibodies.
In marked contrast to poor antibody responses after measles
vaccination in young children with maternal antibody, speciﬁc T
cell responses are induced and are measurable after immunization
in the presence of maternal antibodies [8]. In addition, measles vac-
cination in the presence of maternal antibodies leads to priming of
B cells such that when children are given a booster dose of measles
vaccine, enhanced immune responses are noted [9]. Yet, other stud-
ies have shown that children immunized with measles vaccine in
the presence of maternal antibodies have lower overall antibody
titers after boosting when compared to children who  were seroneg-
ative at the time of initial measles immunization and then boosted
[10].
In an effort to circumvent the effect of maternal antibody on the
primary immune response to measles vaccine in young children,
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).

































































Inhibition of immune responses to vaccines in young children by maternal antibody.*
Vaccine antigen Type of vaccine Reference
numbers
Tetanus Combination protein vaccine [20]
Diphtheria Combination protein vaccine [20]
Haemophilus inﬂuenza,
type b
Protein conjugate vaccine [20]
Pertussis Acellular and whole cell vaccines [21]
Measles Live-attenuated [3–9,15]
Mumps Live-attenuated [15]
Hepatitis A Inactivated virus [22]




Pneumococcal Protein conjugate vaccine [20,27]470 K.M. Edwards / Vacc
igh titer measles vaccines were developed and studied. In a trial
onducted in the Gambia, infants were randomized to receive either
igh titer Edmonston-Zagreb (EZ) measles vaccine at 4 months
f age or lower titer conventional Schwarz measles vaccine at 9
onths age [11]. Measles developed in 2 of 119 children who
eceived the high titer EZ vaccine and in 7 of 120 children who
eceived the lower dose Schwarz vaccine. Serological responses
easured at 5 months after vaccination and at 18 months of age
ere satisfactory in both groups, although antibody levels were on
verage 2-fold higher in the Schwarz group than in the EZ group.
he frequencies of fever, cough, vomiting, and diarrhea were no
igher in the EZ vaccine recipients in the 3 weeks following vac-
ination than in age-matched non-immunized controls. Long-term
orbidity as assessed by clinic attendance and weight at 18 months
f age was much the same in the two groups [11]. However, subse-
uent studies of the high titer measles vaccine demonstrated that
t was associated with increased mortality in female vaccine recip-
ents [12,13]. Although maternal antibody titers were reported to
e lower in girls than in boys, the reason for the increase in adverse
vents after the high titer vaccine in females remains unclear [14].
owever, given the adverse mortality outcomes in females, further
tudies of the high titer EZ vaccines were not pursued.
Another approach to circumvent the effect of maternal anti-
ody on immune responses to measles vaccine in young children
as to attempt to determine the earliest possible time where the
aternal antibody titer would be low enough to permit success-
ul vaccination. Borras and colleagues attempted to determine this
ime by carefully monitoring the decline in maternal antibody dur-
ng the ﬁrst months of life in young infants and determining their
easles antibody titers at ages 9–14 months both before and 28
ays after their vaccination [15]. Seroconversion was deﬁned as
he presence of antibodies after vaccination in subjects without
ntibodies before vaccination. In this study maternal antibodies
ere still present in 45% of children at age 9 months. However,
n those children who were actually seronegative prior to vaccina-
ion, 61% of the children seroconverted after measles vaccination.
orras et al. suggested that changing the ﬁrst dose of measles vac-
ine from age 15 months to age 12 months would be the optimal
accination time [15].
Gans and colleagues attempted to provide greater precision in
etermining the optimal time for measles vaccination in young
hildren. They evaluated neutralizing antibody responses in 6-, 9-
nd 12-month-old infants given measles or mumps  vaccine. They
emonstrated that 6-month-old infants had diminished humoral
mmune responses associated with passive maternal antibody
ffects, but also reported that they had an intrinsic deﬁciency
n antiviral antibody production, which was independent of the
ffects of passive antibody. In contrast, lower neutralizing anti-
ody titers in 9-month-olds were related only to passive antibody
ffects and not to intrinsic deﬁciencies in antibody production. In
urther contrast, measles and mumps-speciﬁc T-cell proliferation
nd interferon-gamma production were induced by vaccination at
, 9 or 12 months of age, regardless of the presence of passive neu-
ralizing antibodies or the age of the child [16]. These observations
uggested that the sensitization of antiviral T-cells occurred in the
resence of passive antibodies and was seen in infants who  did not
evelop active humoral immunity. When a second dose of measles
accine was given at 12–15 months of age, an enhanced antiviral
-cell response to measles was noted in the infants who  were vac-
inated at either 6 or 9 months of age, and higher seroconversion
ates were also noted. Since T-cell immunity is elicited under the
over of passive antibodies, the youngest infants beneﬁt from the
ynergistic protection mediated by maternal antibodies and their
wn capacity to develop sensitized antiviral T-cells [16].
The presence of measles antibody in breast milk has also been
ssessed in a study reported from Nigeria. Maternal and cord bloodInﬂuenza Virus Inactivated vaccine [28]
* Modiﬁed from Ref. [2].
samples were collected from 33 Nigerian mother-infant pairs and
tested for measles-speciﬁc IgG. All these samples had protective
measles antibodies at the time of delivery. Determination of the
rate of waning of these antibodies revealed that 58 per cent of
these children had lost the protective maternal antibody by the
age of 4 months and only 3 per cent of the children had protec-
tive antibody between the ages of 6–9 months. Fifty-ﬁve colostrum
samples from the same mothers and 347 breastmilk samples col-
lected at various periods during breastfeeding also showed that
anti-measles IgA had dropped below the protective cut-off within
the ﬁrst 2 weeks of birth [17]. Thus, these data indicated that Nige-
rian infants were born with anti-measles antibody but that the rate
of waning of both serum and breast milk antibody left many of the
infants unprotected before the ﬁrst dose of the vaccine.
Differences in the actual amounts of maternal antibody
transplacentally provided to the infant exist due to a number of
factors, including whether the maternal antibodies were a result
of wild-type measles infection versus administration of live atten-
uated vaccine. Maternal antibody levels in children of vaccinated
mothers are lower and decline faster than in children from natu-
rally infected mothers [18]. Gans and Maldonado recently discussed
the effect of lower maternal antibody levels resulting from vaccine-
induced immunity when they highlighted that measles outbreaks
in countries with high measles vaccine coverage have been seen
primarily in infants [19]. Further, they speculated that the num-
ber of susceptible infants is expected to increase among highly
vaccinated populations as the majority of women in child-bearing
years have vaccine-induced immunity to measles. Recent studies
show that 99% of infants born to vaccinated mothers lack detectable
measles antibodies by 6 months of age [20,21]. Many of the stud-
ies with measles were conducted at the time of the circulation
of natural measles infection and the widespread use of measles
vaccine for many years has resulted in lower antibody levels in
mothers. Continued assessment of the effect of decreased mater-
nal antibody and the optimal timing for measles vaccination will be
needed.
Other vaccines administered to young children: The effect of
maternal antibody on infant immune responses has been shown
with a number of other vaccines and these are summarized in
Table 1 [22–30]. Vaccine responses are inhibited in the presence of
maternal antibody for many vaccine antigens. Jones et al. recently
reported on the relationship between the concentration of spe-
ciﬁc antibody to Bordetella pertussis, Haemophilus inﬂuenzae type
b (Hib), tetanus toxoid and pneumococcal antigens at birth and
after primary immunization at 2, 3, and 4 months of age to assess
the effect of maternal antibody levels on infant immune responses
[22]. Sera were obtained from the infants at birth and at 5 months
































































Fig. 1. In the presence of measles virus (MV)-speciﬁc maternal antibodies (IgG),
the  ﬁrst signal is down-regulated by a cross-link between B cell receptor (BCR) and
FcRIIB. If MV-speciﬁc IgG binds to MV,  the constant region is bound by the receptor
for  the constant region (Fc) of IgG (which is FcRIIB). FcRIIB is the only Fc-receptor
on B cells and does not bind other immunoglobulins like IgM or IgA. After juxtapo-
sition of the BCR and FcRIIB, the tyrosine-based inhibitory motif of FcRIIB is in
close proximity to the tyrosine-based activation motif of BCR and delivers a negative
signal, as shown by the red line. (For interpretation of the references to color in thisK.M. Edwards / Vacc
f age and speciﬁc antibody concentrations were determined.
ollowing primary immunization, 97% of infants had speciﬁc anti-
ody concentrations associated with protection against Hib, 89%
gainst pertussis and 100% against tetanus. Concentrations of all
peciﬁc antibodies after vaccination were signiﬁcantly higher than
t birth (p < 0.0001), except for antibody titers against tetanus tox-
id. There was an inverse correlation between infant antibody
oncentrations at birth and fold-increases in antibody concen-
ration post-immunization for tetanus, pneumococcus, pertussis,
nd Hib. The highest concentrations of speciﬁc IgG at birth were
ssociated with lower post-immunization titers for tetanus and
neumococcus, but this association was not observed for Hib
r pertussis. The authors concluded that “[h]igher antibody con-
entrations at birth appeared to inhibit the response to infant
mmunization for tetanus and pneumococcus, but the effect was
ess marked for Hib and pertussis, and supports that maternal
mmunization does not inhibit infant immunization responses in
 clinically relevant manner.”
One particularly interesting observation was  made about the
ffect of maternal antibody on the infant immune response to
ither conventional whole cell pertussis (DTP) or acellular pertus-
is vaccines when combined with diphtheria and tetanus toxoids
DTaP) in studies conducted in the 1990s [23]. A total of 2342
nfants were randomized to receive one of 13 different DTaP
ade by different manufacturers and containing different con-
entrations of antigens or 2 licensed DTP vaccines containing
hole cell pertussis antigens at 2, 4, and 6 months of age. The
orrelations between pre-immunization and post-immunization
ntibody titers after three doses of vaccine were modeled by
inear regression. Remarkably, after DTP but not DTaP, higher
evels of pre-existing antibody were associated with substantial
28–56%) reductions in the antibody responses to pertussis toxin
PT). For other pertussis antibodies, modest inverse correlations
ere also seen between pre-existing antibody concentrations and
ost-immunization antibody responses (resulting in 8% to 18%
eductions in post-immunization antibody titers) for both DTP and
TaP. These data are particularly relevant in light of the current rec-
mmendation that all pregnant women in the United States receive
etanus and diphtheria toxoids with acellular pertussis antigens
Tdap) with each pregnancy. The earlier data suggest that the use
f Tdap in pregnancy would be unlikely to adversely affect pertus-
is antibody responses after DTaP given to infants born to mothers
ith high antibody levels. However, studies to assess the effect of
aternal Tdap on infant immune responses to routinely adminis-
ered infant vaccines are ongoing.
Another recently published study suggests that maternal immu-
ization could have adverse implications for immune responses of
nfants to conjugate pneumococcal vaccines [30]. In this random-
zed trial, pregnant women were given either an investigational
-valent pneumococcal conjugate vaccine (PCV-9) or placebo dur-
ng the last trimester of pregnancy with the goal of reducing
arly infant otitis media. Then all infants received 7-valent pneu-
ococcal conjugate vaccine at 2, 4, 6, and 12 months of age.
esults suggested that immunizing pregnant women with PCV-9
ncreased the infants’ risk of acute OM in the ﬁrst 6 months of life,
nd this correlated with decreased infant antibody responses to
everal of the Streptococcus pneumoniae vaccine serotypes. Expla-
ations for these results included dampening of infant antibody
roduction by high levels of passively acquired maternal pneumo-
occal antibodies and/or altered B lymphocyte immune responses
n infants exposed to these speciﬁc polysaccharide antigens in
tero. Additional studies are needed to afﬁrm or refute these
esults.
Siegrist, in her excellent review of the mechanisms responsible
or inhibition by maternal antibody on infant vaccine responses,
ypothesized four speciﬁc mechanisms; (1) neutralization of liveﬁgure legend, the reader is referred to the web version of this article.)
Source: Figure modiﬁed from Ref. [2].
viral vaccines by maternal antibody, (2) epitope masking by mater-
nal antibody, thus preventing antigen binding by infant B cells
and limiting their priming, (3) inhibition of infant B cell activa-
tion by Fc-receptor mediated signaling, and (4) elimination of
maternal antibody-coated vaccine antigens through Fc-dependent
phagocytosis [31]. These mechanisms were further pursued in the
comprehensive discussion by Niewiesk [2]. Although viral neu-
tralization of live attenuated vaccines is often suggested to be
the explanation for poor immune responses in the face of mater-
nal antibody, this explanation does not address why  maternal
antibodies suppress both live and inactivated vaccines and non-
neutralizing antibodies also efﬁciently block vaccine responses [2].
Another common mechanism espoused to explain the inhibition
is epitope masking. However, high concentrations of some anti-
bodies can be less inhibitory than lower concentrations of others.
Further, the inhibition of maternal antibody is often not speciﬁc for
that epitope [2]. One of the most attractive mechanisms hypoth-
esized for the role of maternal antibody on inhibition of vaccine
responses in the infant is the actual inhibition of B cell activa-
tion by the physical cross-linking of the B cell receptor, which
recognizes the maternal antibody, and the Fc receptor which binds
the IgG molecule on the surface of the B cells. This cross-linking
results in a negative signal that inhibits both B cell proliferation
and antibody secretion (Fig. 1). This mechanism is further sup-
ported by the work of Kim et al. who  demonstrated in cotton rats
immunized with live attenuated measles vaccine, that passively
transferred measles-speciﬁc IgG inhibited B-cell responses through
cross-linking of the B-cell receptor with the Fc receptor for IgG.
The extent of inhibition increased with the number of antibod-
ies engaging the Fc receptor [32]. These authors also showed that
this inhibition could be partially overcome by administration of
measles vaccine-speciﬁc monoclonal IgM antibody. The IgM stim-
ulated the B-cell directly through cross-linking the B-cell receptor
via complement protein 3d and antigen to the complement recep-
tor 2 signaling complex. These data convincingly demonstrated
that maternal antibodies inhibit B-cell responses through interac-












































maternal antibodies. Blood 2011;117(June (23)):6143–51, http://dx.doi.org/472 K.M. Edwards / Vacc
he potential for elimination of maternal antibody coated vaccine
ntigens through Fc-dependent phagocytosis has been brought
nto question by studies in knockout mice lacking FC receptors
33].
In summary, the inhibition by maternal antibody of infant vac-
ine responses has been documented for multiple vaccine antigens.
n contrast, the T cell responses are largely not affected. For most
accines, priming occurs in the presence of maternal antibody, but
he extent and magnitude of the booster response may  vary. Mater-
al immunization appears to have an important role in preventing
isease in young infants, and the effect on infant responses will
equire continued evaluation. However, concern over suppression
f immune responses to infant vaccination should not impede fur-
her development and study of maternal immunization programs
gainst important neonatal pathogens.
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